Xeris Biopharma (NASDAQ:XERS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Xeris Biopharma (NASDAQ:XERS) from a buy rating to a strong-buy rating in a report issued on Saturday.

XERS has been the subject of a number of other reports. Barclays started coverage on Xeris Biopharma in a research report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price for the company. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Oppenheimer reissued an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Piper Sandler lifted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $5.60 on Friday. Xeris Biopharma has a 12-month low of $3.81 and a 12-month high of $10.08. The company’s 50 day moving average price is $7.06 and its two-hundred day moving average price is $7.57. The firm has a market cap of $965.61 million, a PE ratio of -559.44 and a beta of 0.61. The company has a quick ratio of 1.57, a current ratio of 2.19 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $85.81 million during the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. Equities research analysts predict that Xeris Biopharma will post -0.41 earnings per share for the current year.

Insider Activity

In other Xeris Biopharma news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $7.09, for a total transaction of $106,350.00. Following the completion of the transaction, the director owned 142,500 shares of the company’s stock, valued at approximately $1,010,325. The trade was a 9.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.08, for a total transaction of $176,341.56. Following the sale, the insider directly owned 2,705,346 shares in the company, valued at $19,153,849.68. This trade represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 240,308 shares of company stock valued at $1,732,453. Corporate insiders own 4.56% of the company’s stock.

Institutional Trading of Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after acquiring an additional 1,358,760 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Xeris Biopharma by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after acquiring an additional 135,815 shares in the last quarter. State Street Corp grew its position in Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after acquiring an additional 378,595 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in Xeris Biopharma by 6.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.